Cargando…

Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a multisystem disorder, but its relationship with kidney injury remains controversial. This study aimed to evaluate MAFLD effects on the chronic kidney disease (CKD) prevalence in a general population in China. METHODS: In t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qian, Chen, Yao, Bao, Ting, Huang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668278/ https://www.ncbi.nlm.nih.gov/pubmed/36374233 http://dx.doi.org/10.1080/0886022X.2022.2144373

Ejemplares similares

Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
por: Lee, Guan Huei, et al.
Publicado: (2020)

The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population
por: Song, Xiao-Hui, et al.
Publicado: (2023)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes
por: Zhou, Qing, et al.
Publicado: (2023)

Optimal timing of coronary angiograms for patients with chronic kidney disease: association between the duration of kidney dysfunction and SYNTAX scores
por: Song, Bei, et al.
Publicado: (2021)

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
por: Sun, Dan-Qin, et al.
Publicado: (2023)

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
por: Wei, Suosu, et al.
Publicado: (2023)

Self-reported snoring is associated with chronic kidney disease in obese but not in normal-weight Chinese adults
por: Jiang, Ziyun, et al.
Publicado: (2021)

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population
por: Gu, Zhan, et al.
Publicado: (2020)

Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease
por: Su, Weitao, et al.
Publicado: (2022)

Methotrexate-Associated Nonalcoholic Fatty Liver Disease with Transaminitis in Rheumatoid Arthritis
por: Sakthiswary, Rajalingham, et al.
Publicado: (2014)

Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors
por: Huang, Xin-Juan, et al.
Publicado: (2023)

Fatty Liver as a Potential Surrogate for Waist Circumference in the Diagnosis of Metabolic Syndrome: A Population-Based Study among Chinese Adults
por: Jiang, Boren, et al.
Publicado: (2018)

Associations of low-carbohydrate with mortality in chronic kidney disease
por: Ren, Qidong, et al.
Publicado: (2023)

Mitofusin-2 gene polymorphisms and metabolic dysfunction associated fatty liver disease: a case-control study in a Chinese population
por: Yuan, Xiwei, et al.
Publicado: (2023)

Neck Circumference Predicts the Occurrence and Remission of Metabolic Associated Fatty Liver Disease: A Longitudinal Study of Community-Dwelling Population
por: Cao, Weijie, et al.
Publicado: (2022)

Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease
por: Kasztelan-Szczerbinska, Beata, et al.
Publicado: (2013)

Prevalence of Chronic Kidney Disease and Its Association with Risk Factors in Disadvantageous Population
por: Huda, Md Nurul, et al.
Publicado: (2012)

Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease
por: Lee, Wei-Chen, et al.
Publicado: (2017)

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
por: Hashimoto, Yoshitaka, et al.
Publicado: (2021)

Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
por: Salgado Alvarez, Giovanni Alejandro, et al.
Publicado: (2022)

Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

The association of echocardiographic parameters on renal outcomes in chronic kidney disease
por: Huang, Tzu-Heng, et al.
Publicado: (2021)

Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B
por: Santos, Cecy Maria de Lima, et al.
Publicado: (2022)

The Severity of Fatty Liver Disease Relating to Metabolic Abnormalities Independently Predicts Coronary Calcification
por: Lee, Ying-Hsiang, et al.
Publicado: (2011)

Health-Related Quality of Life in Chinese Patients with Chronic Liver Disease
por: Gao, Ru, et al.
Publicado: (2012)

Evaluation of cerebral dysfunction in patients with chronic kidney disease using neuropsychometric and neurophysiological tests
por: Sanchez-Meza, Fabiola, et al.
Publicado: (2021)

In vivo recognition of bioactive substances of Polygonum multiflorum for protecting mitochondria against metabolic dysfunction-associated fatty liver disease
por: Yu, Li-Ping, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease
por: Miyamori, Daisuke, et al.
Publicado: (2023)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Relationships between blood bone metabolic biomarkers and anemia in patients with chronic kidney disease
por: Li, Fan, et al.
Publicado: (2023)

Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults
por: Zhang, Junfeng, et al.
Publicado: (2021)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment
por: Yu, Qiang, et al.
Publicado: (2022)

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
por: Huang, Shang-Chin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6kkei6tlberdk1g1rtctfgspj6